Related Experiment Video
Updated: Dec 12, 2025

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Allergic bronchopulmonary aspergillosis misdiagnosed as recurrent pneumonia
1Department of Allergy, Beijing Children's Hospital, Children's National Medical Center, Beijing, China.
Abstract:
Allergic bronchopulmonary aspergillosis (ABPA) is a disease of the lungs resulting from a hypersensitivity reaction to Aspergillus fumigatus. The disease remains underdiagnosed and as many as 57% of patients are misdiagnosed as pulmonary tuberculosis, pneumonia, pulmonary abscess in China. Here we report the case of a 13-year-old girl with ABPA who presented with productive cough, wheezing, bronchiectasis and decline in lung function, total IgE was 25,180 KU/L, Aspergillus-specific IgE was 34.7 kUA/L. Chest high-resolution computed tomography (CT) showed infiltration, central bronchiectasis, and high-attenuation mucus in the left lower lobe and lingula. On bronchoscopy, a large amount of purulent material and brownish sputum plugs were seen. This case has been diagnosed as pneumonia 3 times before the ABPA diagnosis. For the treatment, corticosteroid (prednisone 0.5 mg/kg/day) plus itraconazole (200 mg, twice a day) were initiated. The girl responded well to the therapy. Two weeks later, she was free of symptoms. Lung function nearly improved to normal. One month later, peripheral eosinophil percentage and IgE decreased to 0.7% and 1,3451 KU/L (46% reduction), respectively. However, the trend of A. fumigatus-specific IgE persistently increased during treatment (from 34.7 KU/L to above 100 KU/L). Chest CT showed improvement in pulmonary infiltration. The present case emphasizes the importance of considering the diagnosis of ABPA in children with uncontrolled pneumonia, hypereosinophilia, and bronchiectasis with a previous history of asthma. Total serum IgE is a useful marker of disease activity and success of therapy while the serum A. fumigatus-specific IgE has limited utility in the follow-up of patients with ABPA.
Insights
Allergic bronchopulmonary aspergillosis (ABPA) is often misdiagnosed. Early diagnosis and treatment with corticosteroids and antifungals improve lung function and symptoms in children with ABPA.
Area of Science:
- Pulmonology
- Allergy and Immunology
- Pediatrics
Background:
- Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by hypersensitivity to Aspergillus fumigatus.
- ABPA is frequently underdiagnosed, with a high misdiagnosis rate (up to 57%) as other pulmonary conditions like tuberculosis or pneumonia, particularly in China.
Observation:
- A 13-year-old girl presented with symptoms including productive cough, wheezing, bronchiectasis, and declining lung function.
- Initial diagnostic workup revealed elevated total IgE (25,180 KU/L) and Aspergillus-specific IgE (34.7 kUA/L).
- Chest CT showed characteristic findings of infiltration, central bronchiectasis, and mucus plugging; bronchoscopy revealed purulent material and sputum plugs. The patient had been misdiagnosed with pneumonia three times prior to the ABPA diagnosis.
Findings:
- Treatment with corticosteroids (prednisone) and itraconazole led to rapid symptom resolution and near-normalization of lung function within two weeks.
- Peripheral eosinophil percentage and total IgE levels decreased significantly after one month of treatment.
- Despite clinical improvement, Aspergillus-specific IgE levels paradoxically increased during therapy, suggesting limited utility for monitoring treatment response.
Implications:
- This case highlights the importance of considering ABPA in pediatric patients with persistent pneumonia, hypereosinophilia, and bronchiectasis, especially with a history of asthma.
- Total serum IgE is a valuable marker for assessing ABPA disease activity and treatment efficacy.
- Aspergillus-specific IgE may not be a reliable indicator for monitoring treatment progress in ABPA.
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

